JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

7.44 -0.67

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.44

Max

7.5

Põhinäitajad
By Trading Economics
Sissetulek	3M 12M
Müük	21M 76M
P/E Sektori keskmine	12.312 67.147
Kasumimarginaal	15.633
Töötajad	179
EBITDA	13M 27M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-33.24% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	24M 382M
Eelmine avamishind	8.11
Eelmine sulgemishind	7.44

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.07 / 3.075 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. mai 2026, 23:43 UTC

Uudisväärsed sündmused

New Zealand's Unemployment Rate Falls in 1Q

5. mai 2026, 23:20 UTC

Kuumad aktsiad

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5. mai 2026, 21:48 UTC

Tulu

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5. mai 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

5. mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5. mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5. mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5. mai 2026, 22:08 UTC

Tulu

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5. mai 2026, 22:07 UTC

Tulu

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Rev $1.2B >PAAS

5. mai 2026, 21:42 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:38 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:30 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:29 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:26 UTC

Tulu

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q EPS 39c >ALC.EB

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5. mai 2026, 21:24 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:18 UTC

Tulu

Mistras Backs 2026 Rev $730M-$750M >MG

5. mai 2026, 21:17 UTC

Tulu

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5. mai 2026, 21:15 UTC

Tulu

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5. mai 2026, 21:12 UTC

Tulu

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5. mai 2026, 21:11 UTC

Tulu

SSR Mining 1Q Rev $581.8M >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q Adj EPS $1.15 >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q EPS $1.16 >SSRM

5. mai 2026, 21:08 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:01 UTC

Tulu

Intact Financial 1Q EPS C$4.12 >IFC.T

5. mai 2026, 21:01 UTC

Kuumad aktsiad

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

5. mai 2026, 20:59 UTC

Tulu

Palantir Beat on Every Key Earnings Metric. Why Its Stock Still Fell. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-33.24% langus

12 kuu keskmine prognoos

Keskmine 5 USD -33.24%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.